title: Genomic damage in endstage renal disease-contribution of uremic toxins.
abstract: Patients with end-stage renal disease (ESRD), whether on conservative, peritoneal or hemodialysis therapy, have elevated genomic damage in peripheral blood lymphocytes and an increased cancer incidence, especially of the kidney. The damage is possibly due to accumulation of uremic toxins like advanced glycation endproducts or homocysteine. However, other endogenous substances with genotoxic properties, which are increased in ESRD, could be involved, such as the blood pressure regulating hormones angiotensin II and aldosterone or the inflammatory cytokine TNF-α. This review provides an overview of genomic damage observed in ESRD patients, focuses on possible underlying causes and shows modulations of the damage by modern dialysis strategies and vitamin supplementation.
authors: Institute of Pharmacology and Toxicology, University of Würzburg, Versbacher Straße 9, 97078 Würzburg, Germany. nicole.schupp@toxi.uni-wuerzburg.de
authors: Nicole
authors: N
authors: Schupp
authors: August
authors: A
authors: Heidland
authors: Helga
authors: H
authors: Stopper
mesh_terms: D004249:DNA Damage / Q000187:drug effects; D019587:Dietary Supplements; D006801:Humans; D007676:Kidney Failure, Chronic / Q000235:genetics* / Q000628:therapy; D009153:Mutagens / Q000633:toxicity*; D017582:Renal Replacement Therapy; D014118:Toxins, Biological / Q000633:toxicity*; D014815:Vitamins / Q000494:pharmacology
chemical_list: D009153:Mutagens; D014118:Toxins, Biological; D014815:Vitamins